Search Medical Condition
Please enter condition
Please choose location
 

Esplugas de Llobregat, Spain Clinical Trials

A listing of Esplugas de Llobregat, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (451) clinical trials

CD19 CART Long Term Follow Up (LTFU) Study

Patients are enrolled following completion or early discontinuation from a Novartis sponsored or supported study of CD19 directed CAR T-Cell treatment and will be followed for 15 years post treatment from the last CD19 directed CAR T-Cell treatment. Patients will be monitored for safety and efficacy within the primary treatment ...

Phase N/A

0.0 miles

Learn More »

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

This is a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to <18 years will be enrolled, of which at least 30 will be ...

Phase

0.0 miles

Learn More »

A Clinical Trial to Assess the Effect of HC-SVT-1001 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones

The purpose os this study is to evaluate the safety and effectiveness of HC-SVT-1001 in the surgical treatment of atrophic nonunion in long bones.

Phase

0.0 miles

Learn More »

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

The purpose of this three part study is to evaluate the pharmacokinetics (Part 1), safety/efficacy (Part 2), and long-term follow-up (Part 3) of ombitasvir (OBV), paritaprevir (PTV), ritonavir (RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in pediatric subjects with genotype 1 or 4 chronic hepatitis ...

Phase

0.0 miles

Learn More »

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

To characterize the pharmacokinetic profile of rivaroxaban administered as granules for suspension formulation and to document safety and tolerability

Phase

0.0 miles

Learn More »

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or VKA for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a ...

Phase

0.0 miles

Learn More »

A Study of Safety Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Each subject will undergo a screening period of up to 5 weeks, a treatment period of 2 weeks with PK sample collection, and an extension treatment period of 48 weeks, to allow subjects access to apremilast treatment if medically appropriate (following the completion of the 2 week PK portion). Regardless ...

Phase

0.0 miles

Learn More »

A Safety Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to <4 years of age with refractory partial onset seizures. It is hypothesized that both doses of pregabalin will demonstrate superior efficacy when ...

Phase

0.0 miles

Learn More »

ADVATE Hemophilia A Outcome Database (AHEAD)

The purpose of the study is to document the natural history of hemophilia. A disease and long-term outcomes in terms of effectiveness, safety and quality of life (QoL) in participants receiving ADVATE in routine clinical practice. Participants may use any treatment regimen, including on-demand and prophylaxis using standardized regimens or ...

Phase N/A

0.0 miles

Learn More »

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC).

Phase

0.0 miles

Learn More »